These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 21060940

  • 1. Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity.
    Hill ZB, Perera BG, Maly DJ.
    Mol Biosyst; 2011 Feb; 7(2):447-56. PubMed ID: 21060940
    [Abstract] [Full Text] [Related]

  • 2. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain.
    Johnson TK, Soellner MB.
    Bioconjug Chem; 2016 Jul 20; 27(7):1745-9. PubMed ID: 27266260
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors.
    Register AC, Chakraborty S, Maly DJ.
    Methods Mol Biol; 2017 Jul 20; 1636():79-89. PubMed ID: 28730474
    [Abstract] [Full Text] [Related]

  • 7. Acquisition of a "Group A"-selective Src kinase inhibitor via a global targeting strategy.
    Hah JM, Sharma V, Li H, Lawrence DS.
    J Am Chem Soc; 2006 May 10; 128(18):5996-7. PubMed ID: 16669643
    [Abstract] [Full Text] [Related]

  • 8. The solution structure of Abl SH3, and its relationship to SH2 in the SH(32) construct.
    Gosser YQ, Zheng J, Overduin M, Mayer BJ, Cowburn D.
    Structure; 1995 Oct 15; 3(10):1075-86. PubMed ID: 8590002
    [Abstract] [Full Text] [Related]

  • 9. A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
    Moroco JA, Baumgartner MP, Rust HL, Choi HG, Hur W, Gray NS, Camacho CJ, Smithgall TE.
    Chem Biol Drug Des; 2015 Aug 15; 86(2):144-55. PubMed ID: 25376742
    [Abstract] [Full Text] [Related]

  • 10. Structural basis for selective inhibition of Src family kinases by PP1.
    Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, Ubersax J, Blethrow J, Morgan DO, Shokat KM.
    Chem Biol; 1999 Sep 15; 6(9):671-8. PubMed ID: 10467133
    [Abstract] [Full Text] [Related]

  • 11. Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors.
    Hill ZB, Perera BG, Andrews SS, Maly DJ.
    ACS Chem Biol; 2012 Mar 16; 7(3):487-95. PubMed ID: 22148755
    [Abstract] [Full Text] [Related]

  • 12. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
    Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM, Zhao H, Morgenstern KA.
    Structure; 1999 Jun 15; 7(6):651-61. PubMed ID: 10404594
    [Abstract] [Full Text] [Related]

  • 13. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
    Roskoski R.
    Pharmacol Res; 2015 Apr 15; 94():9-25. PubMed ID: 25662515
    [Abstract] [Full Text] [Related]

  • 14. Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors.
    Gushwa NN, Kang S, Chen J, Taunton J.
    J Am Chem Soc; 2012 Dec 19; 134(50):20214-7. PubMed ID: 23190395
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core.
    Chen S, O'Reilly LP, Smithgall TE, Engen JR.
    J Mol Biol; 2008 Nov 07; 383(2):414-23. PubMed ID: 18775435
    [Abstract] [Full Text] [Related]

  • 16. How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture.
    Fang L, Vilas-Boas J, Chakraborty S, Potter ZE, Register AC, Seeliger MA, Maly DJ.
    ACS Chem Biol; 2020 Jul 17; 15(7):2005-2016. PubMed ID: 32479050
    [Abstract] [Full Text] [Related]

  • 17. Novel mechanism of regulation of the non-receptor protein tyrosine kinase Csk: insights from NMR mapping studies and site-directed mutagenesis.
    Shekhtman A, Ghose R, Wang D, Cole PA, Cowburn D.
    J Mol Biol; 2001 Nov 16; 314(1):129-38. PubMed ID: 11724538
    [Abstract] [Full Text] [Related]

  • 18. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities.
    Liu Y, Witucki LA, Shah K, Bishop AC, Shokat KM.
    Biochemistry; 2000 Nov 28; 39(47):14400-8. PubMed ID: 11087392
    [Abstract] [Full Text] [Related]

  • 19. The Abl SH2-kinase linker naturally adopts a conformation competent for SH3 domain binding.
    Chen S, Brier S, Smithgall TE, Engen JR.
    Protein Sci; 2007 Apr 28; 16(4):572-81. PubMed ID: 17327393
    [Abstract] [Full Text] [Related]

  • 20. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases.
    Nam NH, Lee S, Ye G, Sun G, Parang K.
    Bioorg Med Chem; 2004 Nov 15; 12(22):5753-66. PubMed ID: 15498652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.